Bioxyne Past Earnings Performance

Past criteria checks 0/6

Bioxyne's earnings have been declining at an average annual rate of -68.5%, while the Personal Products industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 32.4% per year.

Key information

-68.5%

Earnings growth rate

-33.5%

EPS growth rate

Personal Products Industry Growth-25.2%
Revenue growth rate32.4%
Return on equity-393.2%
Net Margin-132.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bioxyne makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:BXN Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410-1341
31 Dec 238-1340
30 Sep 237-840
30 Jun 235-230
31 Mar 234-240
31 Dec 222-120
30 Sep 221-110
30 Jun 220010
31 Mar 221010
31 Dec 212010
30 Sep 212010
30 Jun 212010
31 Mar 212-110
31 Dec 202-110
30 Sep 202-110
30 Jun 202-110
31 Mar 202-120
31 Dec 192-120
30 Sep 192-120
30 Jun 192-120
31 Mar 192-120
31 Dec 183-120
30 Sep 182-120
30 Jun 182-120
31 Mar 182-120
31 Dec 172-120
30 Sep 172-110
30 Jun 172-110
31 Mar 172-110
31 Dec 162010
30 Sep 162010
30 Jun 162010
31 Mar 162010
31 Dec 152010
30 Sep 152010
30 Jun 152010
31 Mar 152110
31 Dec 142110
30 Sep 142110
30 Jun 142110
31 Mar 142-210
31 Dec 132-510

Quality Earnings: BXN is currently unprofitable.

Growing Profit Margin: BXN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BXN is unprofitable, and losses have increased over the past 5 years at a rate of 68.5% per year.

Accelerating Growth: Unable to compare BXN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BXN is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (10.4%).


Return on Equity

High ROE: BXN has a negative Return on Equity (-393.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 14:26
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioxyne Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution